Schrödinger

17.09.2020 • Topics • Innovation

Accelerated Drug Discovery

In January, Schrödinger, a provider of integrated software solutions, and the life sciences company Bayer announced a 5-year technology alliance to develop a comprehensive de novo design solution to accelerate the discovery of innovative, high-quality drugs.

29.01.2020 • News

Schrödinger and Bayer to Collaborate on Acceleration of Drug Discovery

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Evonik Operations GmbH (Hanau)

Biobased Feedstocks as a Roadmap to Defossilization

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Schrödinger GmbH